Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02443571 · ClinicalTrials.gov registry record
Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)
A clinical trial of Prostatic Neoplasms, sponsored by Blue Earth Diagnostics.
- Completed
- Registry status
- 714
- Enrollment target
- 4
- Study locations
NCT02443571 is a study of Prostatic Neoplasms that has completed, run by Blue Earth Diagnostics. The registered enrollment target is 714 participants, above the 503-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (42% higher). The trial reports 4 study locations across 2 states.
The verdict
NCT02443571, a study of Prostatic Neoplasms, has completed, sponsored by Blue Earth Diagnostics.
- COMPLETED
- Registry status
- 714 participants
- Enrollment target
- 4
- Study locations
Study Summary
This retrospective observational multi centered study has been established to collect the clinical experience relating to the administration of Fluciclovine 18F employed in both investigator initiated studies and named patient/compassionate use programmes in up to 5 sites.
Conditions Studied
Interventions
- RADIATION Fluciclovine (18F)
Study Locations (4)
Other
- University Hospital Sant'Orsola Malpighi - Bologna
- Oslo University Hospital - Oslo
- Aleris Kreftsenter - Oslo
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2015-01 |
| Est. Completion | 2015-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02443571
The ClinicalTrials.gov registry entry for NCT02443571 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 714 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 503-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (42% higher). The listed sponsor is Blue Earth Diagnostics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Fluciclovine (18F) is the first listed.
NCT02443571 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Georgia.
Frequently Asked Questions
What is clinical trial NCT02443571 about?
NCT02443571 is a clinical study titled "Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)". This retrospective observational multi centered study has been established to collect the clinical experience relating to the administration of Fluciclovine 18F employed in both investigator initiated studies and named patient/compassionate use programmes in up to 5 sites.
What is the current status of trial NCT02443571?
This trial is currently completed. The enrollment target is 714 participants. The study started on 2015-01. Estimated completion is 2015-06.
What conditions does trial NCT02443571 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT02443571?
The interventions under investigation include: Fluciclovine (18F) (RADIATION).
Who is sponsoring clinical trial NCT02443571?
This trial is sponsored by Blue Earth Diagnostics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02443571 being conducted?
This trial has 4 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prostate Active Surveillance Study
RECRUITING
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture
RECRUITING · NA
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
RECRUITING · Phase 1
-
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
RECRUITING
-
Men at High Genetic Risk for Prostate Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.